Research Analysts Issue Forecasts for PLX FY2026 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Analysts at HC Wainwright boosted their FY2026 earnings estimates for Protalix BioTherapeutics in a research note issued on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.26 per share for the year, up from their previous forecast of $0.20. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2026 earnings at $0.01 EPS, Q1 2027 earnings at $0.01 EPS, Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.04 EPS and Q4 2027 earnings at $0.08 EPS.

Protalix BioTherapeutics Stock Performance

Shares of NYSE:PLX opened at $2.23 on Friday. The firm has a fifty day moving average of $2.61 and a 200 day moving average of $2.20. Protalix BioTherapeutics has a 52-week low of $1.32 and a 52-week high of $3.19. The firm has a market capitalization of $179.34 million, a PE ratio of -17.15 and a beta of -0.26.

Hedge Funds Weigh In On Protalix BioTherapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC bought a new position in shares of Protalix BioTherapeutics during the second quarter valued at about $1,223,000. Jane Street Group LLC increased its stake in shares of Protalix BioTherapeutics by 894.3% during the fourth quarter. Jane Street Group LLC now owns 289,917 shares of the company’s stock valued at $522,000 after buying an additional 326,417 shares during the period. Goldman Sachs Group Inc. raised its holdings in Protalix BioTherapeutics by 482.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 289,461 shares of the company’s stock worth $741,000 after purchasing an additional 239,751 shares in the last quarter. Evergreen Capital Management LLC bought a new position in Protalix BioTherapeutics in the second quarter worth about $254,000. Finally, Round Rock Advisors LLC bought a new position in shares of Protalix BioTherapeutics in the 4th quarter worth approximately $279,000. Institutional investors own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.